Pular para o conteúdo principal
Ranking Invest

XENE - Xenon Pharmaceuticals Inc.

Segmento: HealthcareXenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Análise Ranking Invest

Valuation estimado
$ 276.15 Mi
IVR
0.05A companhia vale 0,05 vezes o seu valor de mercado atual de acordo com a estimativa do Ranking Invest.
IVR2
-0.17O valuation alternativo equivale a -17% do valor de mercado da companhia.
MLL
-0.17O lucro líquido dos controladores em 16 trimestres equivale a -17% do valor de mercado.
Último Balanço Atualizado: 2T2026

O Ranking Invest utiliza metodologia própria baseada em dados financeiros objetivos, considerando patrimônio, lucratividade e endividamento para estimar o valuation das empresas.

Dados da Empresa

Patrimônio Líquido

$ 1.24 Bi

Dívida Líquida

-$ 119.53 Mi

L4T

-$ 409.19 Mi

Indicadores Básicos

ROE

-32.94%

Índices de Previsibilidade

Receita Líquida

G1.65

Lucro

A0.11

Margem

E1.09

Índices de Tendência

Receita Líquida

D-1.73

Lucro

G-11.36

Margem

B5.57

Índices de Endividamento

DIV/PAT

-0.10

DIV/L4T

0.29

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.